Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

lancet-labs

Lancet Labs, News on Lancet Labs, stories on Lancet Labs, articles on Lancet Labs, Lancet Labs stories at Wion, Lancet Labs news, Lancet Labs latest news

lancet labs

Lancet opens probe into ‘unreliable’ anti-stroke medicine